drugset / Trial / NCT00177619
Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)
Phase 3
Completed
120 enrolled
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The overall goal of this proposal is to determine the effectiveness and safety of once weekly alendronate (Fosamax) in the prevention and treatment of osteoporosis in men with prostate cancer on androgen deprivation therapy and to evaluate maintenance of bone mass following termination of therapy after one year.
Timeline
- Start
- 2002-05
- Primary completion
- 2005-12
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | — | — |